{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:43:40Z","timestamp":1787240620915,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1038\/s41416-018-0088-8","type":"journal-article","created":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T09:10:40Z","timestamp":1525943440000},"page":"1289-1295","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy"],"prefix":"10.1038","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7972-9050","authenticated-orcid":false,"given":"Nikki R.","family":"Adler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant A.","family":"McArthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Haydon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona A.","family":"McLean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria J.","family":"Mar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,14]]},"reference":[{"key":"88_CR1","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/ajd.12662","volume":"58","author":"DE Gyorki","year":"2017","unstructured":"Gyorki, D. E. et al. When is a sentinel node biopsy indicated for patients with primary melanoma? An update of the \u2018Australian guidelines for the management of cutaneous melanoma\u2019. Australas. J. Dermatol. 58, 274\u2013277 (2017).","journal-title":"Australas. J. Dermatol."},{"key":"88_CR2","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa1310460","volume":"370","author":"DL Morton","year":"2014","unstructured":"Morton, D. L. et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N. Engl. J. Med 370, 599\u2013609 (2014).","journal-title":"N. Engl. J. Med"},{"key":"88_CR3","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1001\/jamasurg.2013.1335","volume":"148","author":"EL Jones","year":"2013","unstructured":"Jones, E. L. et al. Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result. JAMA Surg. 148, 456\u2013461 (2013).","journal-title":"JAMA Surg."},{"key":"88_CR4","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1245\/ASO.2005.03.074","volume":"12","author":"VS Yee","year":"2005","unstructured":"Yee, V. S. et al. Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy. Ann. Surg. Oncol. 12, 429\u2013439 (2005).","journal-title":"Ann. Surg. Oncol."},{"key":"88_CR5","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/ijc.10978","volume":"104","author":"KS Smalley","year":"2003","unstructured":"Smalley, K. S. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J. Cancer 104, 527\u2013532 (2003).","journal-title":"Int J. Cancer"},{"key":"88_CR6","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/j.1755-148X.2011.00873.x","volume":"24","author":"B Devitt","year":"2011","unstructured":"Devitt, B. et al. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res. 24, 666\u2013672 (2011).","journal-title":"Pigment Cell Melanoma Res."},{"key":"88_CR7","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/humu.20481","volume":"28","author":"T Hocker","year":"2007","unstructured":"Hocker, T. & Tsao, H. Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum. Mutat. 28, 578\u2013588 (2007).","journal-title":"Hum. Mutat."},{"key":"88_CR8","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/sj.jid.5700632","volume":"127","author":"W Liu","year":"2007","unstructured":"Liu, W. et al. Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. J. Invest Dermatol. 127, 900\u2013905 (2007).","journal-title":"J. Invest Dermatol."},{"key":"88_CR9","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","volume":"29","author":"GV Long","year":"2011","unstructured":"Long, G. V. et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 29, 1239\u20131246 (2011).","journal-title":"J. Clin. Oncol."},{"key":"88_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","volume":"150","author":"E Hodis","year":"2012","unstructured":"Hodis, E. et al. A landscape of driver mutations in melanoma. Cell 150, 251\u2013263 (2012).","journal-title":"Cell"},{"key":"88_CR11","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1016\/j.ejca.2014.06.009","volume":"50","author":"AP Barbour","year":"2014","unstructured":"Barbour, A. P. et al. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy. Eur. J. Cancer 50, 2668\u20132676 (2014).","journal-title":"Eur. J. Cancer"},{"key":"88_CR12","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","volume":"30","author":"M Colombino","year":"2012","unstructured":"Colombino, M. et al. BRAF\/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J. Clin. Oncol. 30, 2522\u20132529 (2012).","journal-title":"J. Clin. Oncol."},{"key":"88_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1158\/1078-0432.CCR-10-2276","volume":"17","author":"JA Ellerhorst","year":"2011","unstructured":"Ellerhorst, J. A. et al. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin. Cancer Res 17, 229\u2013235 (2011).","journal-title":"Clin. Cancer Res"},{"key":"88_CR14","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.jaad.2015.02.1113","volume":"72","author":"SY Kim","year":"2015","unstructured":"Kim, S. Y. et al. Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma. J. Am. Acad. Dermatol. 72, 1036\u20131046 (2015).","journal-title":"J. Am. Acad. Dermatol."},{"key":"88_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/1755-8794-7-23","volume":"7","author":"SQ Wong","year":"2014","unstructured":"Wong, S. Q. et al. Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. BMC Med. Genom. 7, 23 (2014).","journal-title":"BMC Med. Genom."},{"key":"88_CR16","first-page":"6483","volume":"9","author":"K Omholt","year":"2003","unstructured":"Omholt, K., Platz, A., Kanter, L., Ringborg, U. & Hansson, J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin. Cancer Res 9, 6483\u20136488 (2003).","journal-title":"Clin. Cancer Res"},{"key":"88_CR17","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1245\/s10434-012-2457-5","volume":"19","author":"S Moreau","year":"2012","unstructured":"Moreau, S. et al. Prognostic value of BRAF(V600) mutations in melanoma patients after resection of metastatic lymph nodes. Ann. Surg. Oncol. 19, 4314\u20134321 (2012).","journal-title":"Ann. Surg. Oncol."},{"key":"88_CR18","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/bjd.13756","volume":"173","author":"VJ Mar","year":"2015","unstructured":"Mar, V. J. et al. The role of BRAF mutations in primary melanoma growth rate and survival. Br. J. Dermatol. 173, 76\u201382 (2015).","journal-title":"Br. J. Dermatol."},{"key":"88_CR19","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jaad.2013.10.064","volume":"70","author":"E Nagore","year":"2014","unstructured":"Nagore, E. et al. Prognostic value of BRAF mutations in localized cutaneous melanoma. J. Am. Acad. Dermatol. 70, 858\u2013862 (2014).","journal-title":"J. Am. Acad. Dermatol."},{"key":"88_CR20","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long, G. V. et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N. Engl. J. Med 377, 1813\u20131823 (2017).","journal-title":"N. Engl. J. Med"},{"key":"88_CR21","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber, J. et al. Adjuvant Nivolumab versus Ipilimumab in resected stage III or IV melanoma. N. Engl. J. Med 377, 1824\u20131835 (2017).","journal-title":"N. Engl. J. Med"},{"key":"88_CR22","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1200\/JCO.1998.16.6.2253","volume":"16","author":"JE Gershenwald","year":"1998","unstructured":"Gershenwald, J. E. et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J. Clin. Oncol. 16, 2253\u20132260 (1998).","journal-title":"J. Clin. Oncol."},{"key":"88_CR23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1159\/000136795","volume":"73","author":"V Giorgi De","year":"2007","unstructured":"De Giorgi, V. et al. Outcome of patients with melanoma and histologically negative sentinel lymph nodes: one institution\u2019s experience. Oncology 73, 401\u2013406 (2007).","journal-title":"Oncology"},{"key":"88_CR24","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/SLA.0b013e3181855718","volume":"248","author":"GW Carlson","year":"2008","unstructured":"Carlson, G. W. et al. Regional recurrence after negative sentinel lymph node biopsy for melanoma. Ann. Surg. 248, 378\u2013386 (2008).","journal-title":"Ann. Surg."},{"key":"88_CR25","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1001\/archsurg.134.4.381","volume":"134","author":"MA Gadd","year":"1999","unstructured":"Gadd, M. A. et al. Outcome of patients with melanoma and histologically negative sentinel lymph nodes. Arch. Surg. 134, 381\u2013387 (1999).","journal-title":"Arch. Surg."},{"key":"88_CR26","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/archsurg.140.9.865","volume":"140","author":"TG Zogakis","year":"2005","unstructured":"Zogakis, T. G. et al. Melanoma recurrence patterns after negative sentinel lymphadenectomy. Arch. Surg. 140, 865\u2013871 (2005).","journal-title":"Arch. Surg."},{"key":"88_CR27","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1245\/s10434-007-9357-0","volume":"14","author":"KM Dalal","year":"2007","unstructured":"Dalal, K. M., Patel, A., Brady, M. S., Jaques, D. P. & Coit, D. G. Patterns of first-recurrence and post-recurrence survival in patients with primary cutaneous melanoma after sentinel lymph node biopsy. Ann. Surg. Oncol. 14, 1934\u20131942 (2007).","journal-title":"Ann. Surg. Oncol."},{"key":"88_CR28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/CMR.0000000000000211","volume":"26","author":"EP O\u2019Connell","year":"2016","unstructured":"O\u2019Connell, E. P., O\u2019Leary, D. P., Fogarty, K., Khan, Z. J. & Redmond, H. P. Predictors and patterns of melanoma recurrence following a negative sentinel lymph node biopsy. Melanoma Res. 26, 66\u201370 (2016).","journal-title":"Melanoma Res."},{"issue":"12","key":"88_CR29","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1016\/j.jid.2017.07.006","volume":"137","author":"Maximilian Gassenmaier","year":"2017","unstructured":"Gassenmaier, M. et al. Serial or parallel metastasis of cutaneous melanoma? A study of the german central malignant melanoma registry. J. Invest. Dermatol. 137, 2570\u20132577 (2017).","journal-title":"Journal of Investigative Dermatology"},{"key":"88_CR30","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1245\/s10434-016-5566-8","volume":"24","author":"M Faut","year":"2017","unstructured":"Faut, M. et al. Nodular histologic subtype and ulceration are tumor factors associated with high risk of recurrence in sentinel node-negative melanoma patients. Ann. Surg. Oncol. 24, 142\u2013149 (2017).","journal-title":"Ann. Surg. Oncol."},{"key":"88_CR31","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries, M. B. et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N. Eng. J. Med 376, 2211\u20132222 (2017).","journal-title":"N. Eng. J. Med"},{"key":"88_CR32","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S0001-7310(07)70128-X","volume":"98","author":"A Tejera-Vaquerizo","year":"2007","unstructured":"Tejera-Vaquerizo, A. et al. Longitudinal study of different metastatic patterns in the progression of cutaneous melanoma. Actas Dermosifiliogr. 98, 531\u2013538 (2007).","journal-title":"Actas Dermosifiliogr."},{"key":"88_CR33","doi-asserted-by":"publisher","first-page":"e32955","DOI":"10.1371\/journal.pone.0032955","volume":"7","author":"L Mervic","year":"2012","unstructured":"Mervic, L. Time course and pattern of metastasis of cutaneous melanoma differ between men and women. PLoS ONE 7, e32955 (2012).","journal-title":"PLoS ONE"},{"issue":"35","key":"88_CR34","doi-asserted-by":"publisher","first-page":"10995","DOI":"10.1073\/pnas.1508074112","volume":"112","author":"J. Zachary Sanborn","year":"2015","unstructured":"Sanborn, J. Z. et al. Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proc. Natl Acad. Sci. USA 112: 10995\u201311000 (2015).","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"88_CR35","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/01.sla.0000181092.50141.fa","volume":"242","author":"DL Morton","year":"2005","unstructured":"Morton, D. L. et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann. Surg. 242, 302\u2013313 (2005).","journal-title":"Ann. Surg."},{"key":"88_CR36","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1245\/s10434-009-0858-x","volume":"17","author":"CR Scoggins","year":"2010","unstructured":"Scoggins, C. R. et al. Factors associated with false-negative sentinel lymph node biopsy in melanoma patients. Ann. Surg. Oncol. 17, 709\u2013717 (2010).","journal-title":"Ann. Surg. Oncol."},{"key":"88_CR37","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1245\/s10434-006-9066-0","volume":"13","author":"ZI Nowecki","year":"2006","unstructured":"Nowecki, Z. I., Rutkowski, P., Nasierowska-Guttmejer, A. & Ruka, W. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma. Ann. Surg. Oncol. 13, 1655\u20131663 (2006).","journal-title":"Ann. Surg. Oncol."},{"key":"88_CR38","doi-asserted-by":"crossref","unstructured":"Nieweg, O. E., Cooper, A., & Thompson, J. F. Role of sentinel lymph node biopsy as a staging procedure in patients with melanoma: a critical appraisal. Australas J. Derm. 58, 268\u2013273 (2017).","DOI":"10.1111\/ajd.12655"},{"key":"88_CR39","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1177\/0194599811408554","volume":"145","author":"N Rosa de","year":"2011","unstructured":"de Rosa, N. et al. Sentinel node biopsy for head and neck melanoma: a systematic review. Otolaryngol. Head. Neck Surg. 145, 375\u2013382 (2011).","journal-title":"Otolaryngol. Head. Neck Surg."},{"key":"88_CR40","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1097\/00000478-200309000-00002","volume":"27","author":"LX Li","year":"2003","unstructured":"Li, L. X. et al. Pathologic review of negative sentinel lymph nodes in melanoma patients with regional recurrence: a clinicopathologic study of 1152 patients undergoing sentinel lymph node biopsy. Am. J. Surg. Pathol. 27, 1197\u20131202 (2003).","journal-title":"Am. J. Surg. Pathol."},{"key":"88_CR41","doi-asserted-by":"publisher","first-page":"e754","DOI":"10.1002\/hed.24094","volume":"38","author":"AH Kaveh","year":"2016","unstructured":"Kaveh, A. H. et al. Aberrant lymphatic drainage and risk for melanoma recurrence after negative sentinel node biopsy in middle-aged and older men. Head. Neck 38, e754\u201360 (2016).","journal-title":"Head. Neck"},{"key":"88_CR42","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1002\/ijc.25747","volume":"129","author":"L Kretschmer","year":"2011","unstructured":"Kretschmer, L. et al. Age as a key factor influencing metastasizing patterns and disease-specific survival after sentinel lymph node biopsy for cutaneous melanoma. Int J. Cancer 129, 1435\u20131442 (2011).","journal-title":"Int J. Cancer"},{"key":"88_CR43","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/jso.24743","volume":"116","author":"AJ Sinnamon","year":"2017","unstructured":"Sinnamon, A. J. et al. Predictors of false negative sentinel lymph node biopsy in trunk and extremity melanoma. J. Surg. Oncol. 116, 848\u2013855 (2017).","journal-title":"J. Surg. Oncol."},{"key":"88_CR44","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1245\/s10434-013-3464-x","volume":"21","author":"CM Balch","year":"2014","unstructured":"Balch, C. M. et al. Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. Ann. Surg. Oncol. 21, 1075\u20131081 (2014).","journal-title":"Ann. Surg. Oncol."},{"key":"88_CR45","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1245\/s10434-015-4538-8","volume":"22","author":"MW Cavanaugh-Hussey","year":"2015","unstructured":"Cavanaugh-Hussey, M. W., Mu, E. W., Kang, S., Balch, C. M. & Wang, T. Older age is associated with a higher incidence of melanoma death but a lower incidence of sentinel lymph node metastasis in the SEER databases (2003-2011). Ann. Surg. Oncol. 22, 2120\u20132126 (2015).","journal-title":"Ann. Surg. Oncol."},{"key":"88_CR46","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1245\/ASO.2004.03.044","volume":"11","author":"VK Sondak","year":"2004","unstructured":"Sondak, V. K. et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann. Surg. Oncol. 11, 247\u2013258 (2004).","journal-title":"Ann. Surg. Oncol."},{"key":"88_CR47","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1245\/s10434-009-0420-x","volume":"16","author":"WC Conway","year":"2009","unstructured":"Conway, W. C. et al. Age-related lymphatic dysfunction in melanoma patients. Ann. Surg. Oncol. 16, 1548\u20131552 (2009).","journal-title":"Ann. Surg. Oncol."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0088-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0088-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0088-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:02:18Z","timestamp":1684602138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-018-0088-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["88"],"URL":"https:\/\/doi.org\/10.1038\/s41416-018-0088-8","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"16 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This was a study of participants in the Melbourne Melanoma Project (MMP), which includes patients referred to one of three tertiary referral centres in Melbourne, Australia (Victorian Melanoma Service at The Alfred Hospital, Peter MacCallum Cancer Centre and the Olivia Newton-John Cancer Research Institute at the Austin Hospital). Institutional ethics approval was obtained from the contributing sites (Project Number 07\/38).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The study was performed in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}